Mereo BioPharma Group plc
NASDAQ:MREO · NASDAQ Global Market
+$0.03 today
Vol 2.58M · Avg 3.36M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-102.4%
avg 40.6%
ROIC
-91.5%
avg -48.9%
ROA
-91.2%
avg -58.2%
Analysis
ROA is currently the strongest return metric at -91.2% versus its period average of -58.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Denise Scots-Knight | Co-Founder, Chief Executive Officer & Executive Director | $686,844.00 | — | 67 | $1.03M | 0.65% |
Charles Sermon | Co-Founder, General Counsel, Business Development & Company Secretary | $536,437.00 | — | 57 | $295,000.00 | 0.18% |
Christine Fox | Chief Financial Officer | $497,202.00 | — | 45 | $105,250.00 | 0.07% |
Jackie Parkin | Senior Vice President & Therapeutic Head | — | — | 68 | — | — |
John A. Lewicki | Chief Scientific Officer | — | — | 74 | $145,000.00 | 0.09% |
Ogun Sazova | VP & Head of Medical Affairs | — | — | — | — | — |
Bo Kara | Senior Vice President and Head of Pharmaceutical Development & CMC | — | — | — | — | — |
Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning | — | — | 55 | $195,000.00 | 0.12% |
Bal Lally | VP & Head of HR | — | — | — | — | — |
Bharti Navsariwala | VP & Head of Regulatory Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.28B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$477.61M
Candel Therapeutics, Inc.
NASDAQ:CADL
$445.70M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$402.82M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$364.78M
Silence Therapeutics plc
NASDAQ:SLN
$324.26M
AC Immune S.A.
NASDAQ:ACIU
$242.71M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$174.37M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$114.91M
Immutep Limited
NASDAQ:IMMP
$55.57M
Who manages MREO?
Mereo BioPharma Group plc (MREO) lists 10 active executives. The top listed executive is Denise Scots-Knight, Co-Founder, Chief Executive Officer & Executive Director.
Are MREO insiders buying or selling?
Recent insider activity shows net selling of $2.44M.
Explore More
Continue the stock analysis
Jump to another research area for this company.